Lucy has experience of patent work both in-house and in private practice and has been involved in drafting, prosecution, opposition and litigation as well as providing legal opinions. She has wide-ranging experience, including of developing filing and prosecution strategies for patent families covering more than 80 countries worldwide, particular expertise in IP issues in Russia and the former CIS region, and knowledge relating to regulatory data exclusivity for biotechnological products and the experimental use and Bolar exemptions from infringement. She has also been involved both in drafting many patent applications and in analysing the value of third party patents and patent applications, so she has a good understanding of how to prepare patent applications that are attractive to potential investors and licensees.
Since joining J A Kemp from GlaxoSmithKline (GSK), Lucy has worked with a range of clients from small start-ups to large pharmaceutical companies and US and Japanese law firms. Whilst in industry she was involved in many contentious proceedings including multiple EPO oppositions, and she now continues to build on this experience by defending the patents of a large pharmaceutical company in the area of injectable polypeptides.
In terms of technologies, Lucy has highly specialised expertise in the field of vaccines, together with experience in the fast-developing field of bioinformatics, in particular, and competence across a wide range of disciplines including antibodies, diagnostics methods and biomarkers.
Lucy joined J A Kemp as an associate in 2014 after working in-house since 2008. She became a partner in 2018.
University of Oxford, Masters in Biochemistry and Molecular Cell Biology (MBioch); Queen Mary University of London, Masters in Intellectual Property Law (MSc)
European Patent Attorney, UK Chartered Patent Attorney
Fellow of the Chartered Institute of Patent Attorneys (CIPA), Member of the Institute of Professional Representatives before the European Patent Office (EPI)